• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Improving Anticoagulant Treatment Strategies of Atrial Fibrillation Using Reinforcement Learning
AMIA Annu Symp Proc. 2021 Jan 25;2020:1431-1440. eCollection 2020.ABSTRACTIn this paper, we developed a personalized anticoagulant treatment recommendation model for atrial fibrillation (AF) patients based on reinforcement learning (RL) and evaluated the effectiveness of the model in terms of short-term and long-term outcomes. The data used in our work were baseline and follow-up data of 8,540 AF patients with high risk of stroke, enrolled in the Chinese Atrial Fibrillation Registry (CAFR) study during 2011 to 2018. We found that in 64.98% of patient visits, the anticoagulant treatment recommended by the RL model were conc...
Source: AMIA Annual Symposium Proceedings - May 3, 2021 Category: Bioinformatics Authors: Lei Zuo Xin Du Wei Zhao Chao Jiang Shijun Xia Liu He Rong Liu Ribo Tang Rong Bai Jianzeng Dong Xingzhi Sun Gang Hu Guotong Xie Changsheng Ma Source Type: research

Late-Breaking Phase 2 Data for Investigational Oral Factor XIa Inhibitor Milvexian Suggest Favorable Antithrombotic Profile Across a Wide Range of Doses
This study establishes proof-of-principle for milvexian as a differentiated antithrombotic agent,” said Jeffrey Weitz, M.D., Professor of Medicine & Biochemistry and Biomedical Sciences at McMaster University and Executive Director of the Thrombosis and Atherosclerosis Research Institute.[i] “Furthermore, the consistently low rates of bleeding across a 16-fold range of milvexian doses suggest that it has a wide therapeutic window, which opens the opportunity to explore milvexian across a broad range of patients including those for whom factor Xa inhibitors are underutilized or not indicated.” The trial met both o...
Source: Johnson and Johnson - November 15, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

A Real-World Exploration into Clinical Outcomes of Direct Oral Anticoagulant Dosing Regimens in Morbidly Obese Patients Using Data-Driven Approaches
ConclusionData-driven approaches can identify key factors associated with clinical outcomes following the dosing of DOACs in morbidly obese patients. This will help design further studies to explore well tolerated and effective DOAC doses for morbidly obese patients.
Source: American Journal of Cardiovascular Drugs - March 6, 2023 Category: Cardiology Source Type: research

Factors Influencing Hospital Length of Stay After Robotic Totally Endoscopic Coronary Artery Bypass Grafting ORIGINAL ARTICLES: ADULT CARDIAC
Conclusions Multiple variables affect LOS after TECAB. Older patients, patients on hemodialysis, patients with cerebrovascular disease, and those with higher general risk scores should expect prolonged LOS. Intraoperative surgical difficulties and conversion to open coronary artery bypass grafting also lead to extended LOS. Postoperative events that are known to prolong LOS in open coronary artery bypass grafting also prolong LOS after TECAB.
Source: The Annals of Thoracic Surgery - February 28, 2013 Category: Cardiovascular & Thoracic Surgery Authors: Lee, J. D., Bonaros, N., Hong, P. T., Kofler, M., Srivastava, M., Herr, D. L., Lehr, E. J., Bonatti, J. Tags: Coronary disease ORIGINAL ARTICLES: ADULT CARDIAC Source Type: research

Pages: 1  2  3  4  5  6  7  8  9